This drug is not commonly used in canine medicine compared with other NSAIDs but has been used for post-operative pain relief, acute gastric injuries associated with endotoxemia (e.g. intussusception, gastric dilation-volvulus).
Due to its potents COX-1 and COX-2 inhibitory activities, flunixin should be given for less than 5 days to minimize side-effects.
Prolonged used is associated with gastroenteritis, hepatotoxicity, coagulopathy and acute renal injury, characterized by elevated GGT, gastritis and prolonged prothrombin and partial prothrombin clotting times.
Recommended dose rate in dogs is 0.5 - 2.2 mg/kg given intramuscularly or subcutaneously once daily for 3 days, then repeated after 4 days.
- ↑ Gilmour MA & Payton ME (2012) Comparison of the effects of IV administration of meloxicam, carprofen, and flunixin meglumine on prostaglandin E(2) concentration in aqueous humor of dogs with aqueocentesis-induced anterior uveitis. Am J Vet Res 73(5):698-703
- ↑ Lees P et al (2004) PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology. J Vet Pharmacol Ther 27(6):491-502
- ↑ KuKanich B et al (2012) Clinical pharmacology of nonsteroidal anti-inflammatory drugs in dogs. Vet Anaesth Analg 39(1):69-90
- ↑ Luna SP et al (2007) Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. Am J Vet Res 68(3):258-264
- ↑ Ogino T et al (2005) Pharmacokinetic interactions of flunixin meglumine and enrofloxacin in dogs. Am J Vet Res 66(7):1209-1213